Stock Track | Innovent Biologics Plummets 5.01% Intraday on Pfizer Deal Regulatory Concerns and Biotech Sector Selloff

Stock Track06-02

Innovent Biologics' stock plummeted 5.01% during intraday trading on Tuesday, as the biotech company faced selling pressure amid regulatory uncertainty surrounding its landmark collaboration with Pfizer.

The decline follows market concerns about the regulatory approval required for Innovent's $10.5 billion global strategic collaboration with Pfizer, which covers 12 early-stage oncology programs. Investors are particularly worried about potential tightening of biomedical technology out-licensing regulations under the COINS Act framework, which could impact the deal's completion.

The broader biotech sector also experienced significant selling pressure during the session, with multiple peers including Akeso, 3SBio, BeiGene, SKB Bio, and Remegen all declining sharply, creating systemic drag on Innovent's stock performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1101740749?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 09:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101740749","market":"hk","top_or_hot":-1,"title":"Stock Track | Innovent Biologics Plummets 5.01% Intraday on Pfizer Deal Regulatory Concerns and Biotech Sector Selloff","media":"Stock Track","content":"<p>Innovent Biologics' stock plummeted 5.01% during intraday trading on Tuesday, as the biotech company faced selling pressure amid regulatory uncertainty surrounding its landmark collaboration with Pfizer.</p><p>The decline follows market concerns about the regulatory approval required for Innovent's $10.5 billion global strategic collaboration with Pfizer, which covers 12 early-stage oncology programs. Investors are particularly worried about potential tightening of biomedical technology out-licensing regulations under the COINS Act framework, which could impact the deal's completion.</p><p>The broader biotech sector also experienced significant selling pressure during the session, with multiple peers including Akeso, 3SBio, BeiGene, SKB Bio, and Remegen all declining sharply, creating systemic drag on Innovent's stock performance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Innovent Biologics Plummets 5.01% Intraday on Pfizer Deal Regulatory Concerns and Biotech Sector Selloff</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Innovent Biologics Plummets 5.01% Intraday on Pfizer Deal Regulatory Concerns and Biotech Sector Selloff\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-02 09:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Innovent Biologics' stock plummeted 5.01% during intraday trading on Tuesday, as the biotech company faced selling pressure amid regulatory uncertainty surrounding its landmark collaboration with Pfizer.</p><p>The decline follows market concerns about the regulatory approval required for Innovent's $10.5 billion global strategic collaboration with Pfizer, which covers 12 early-stage oncology programs. Investors are particularly worried about potential tightening of biomedical technology out-licensing regulations under the COINS Act framework, which could impact the deal's completion.</p><p>The broader biotech sector also experienced significant selling pressure during the session, with multiple peers including Akeso, 3SBio, BeiGene, SKB Bio, and Remegen all declining sharply, creating systemic drag on Innovent's stock performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1101740749","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101740749","pubTimestamp":1780364931,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Innovent Biologics' stock plummeted 5.01% during intraday trading on Tuesday, as the biotech company faced selling pressure amid regulatory uncertainty surrounding its landmark collaboration with...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"个股追踪|辉瑞交易监管担忧及生物科技板块抛售信达生物盘中暴跌5.01%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"Innovent Biologics' stock plummeted 5.01% during intraday trading on Tuesday, as the biotech company faced selling pressure amid regulatory uncertainty surrounding its landmark collaboration with Pfizer.The decline follows market concerns about the regulatory approval required for Innovent's $10.5 billion global strategic collaboration with Pfizer, which covers 12 early-stage oncology programs. Investors are particularly worried about potential tightening of biomedical technology out-licensing regulations under the COINS Act framework, which could impact the deal's completion.The broader biotech sector also experienced significant selling pressure during the session, with multiple peers including Akeso, 3SBio, BeiGene, SKB Bio, and Remegen all declining sharply, creating systemic drag on Innovent's stock performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1101740749","isCrawlerRequest":true}